Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001610717-26-000125
Filing Date
2026-03-19
Accepted
2026-03-19 18:41:25
Documents
1
Period of Report
2026-03-17

Document Format Files

Seq Description Document Type Size
1 form4.html 4  
1 form4.xml 4 3289
  Complete submission text file 0001610717-26-000125.txt   4773
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Issuer) CIK: 0001501989 (see all company filings)

EIN.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD, SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address
Chu Yu-Waye (Reporting) CIK: 0001854586 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37587 | Film No.: 26775568